Approved

Ono Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

ONO Receives a Manufacturing and Marketing Approval of Adlumiz®, a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

Lead Product(s): Anamorelin HCl

Therapeutic Area: Nutrition and Weight Loss Product Name: Adlumiz

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2021

Details:

Marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”) is mainly based on the results from the ONO-7643-04 and ONO-7643-05 studies conducted in Japan in patients with cancer cachexia.

PDL BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation

Lead Product(s): Deoxycholic Acid

Therapeutic Area: Nutrition and Weight Loss Product Name: Kybella

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: SWK Holdings Corporation

Deal Size: $4.3 million Upfront Cash: $4.3 million

Deal Type: Divestment August 31, 2020

Details:

Under the terms of the definitive agreement, PDL BioPharma will sale three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK Funding, LLC a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH).